HOME >> MEDICINE >> NEWS
Enhanced external counterpulsation reduces angina, says University of Pittsburgh study

PITTSBURGH, Feb. 27 Patients with angina (chest pain) and left ventricular dysfunction respond very well to treatment using enhanced external counterpulsation (EECP), with little or no future heart failure events, according to researchers from the Cardiovascular Institute at the University of Pittsburgh Medical Center (UPMC). The researchers suggest that EECP is an effective therapy for the 2.4 million Americans with coronary artery disease who are not candidates for invasive revascularization procedures, such as balloon angioplasty, heart bypass or stent implantation. Their findings were reported in the January issue of the American Journal of Cardiology.

EECP is a non-invasive circulatory procedure whereby long inflatable cuffs are wrapped around a patient's calves, thighs and buttocks. While the patient lies on a table, the cuffs are sequentially inflated while the heart is at rest (diastole), and then simultaneously deflated just before the heart begins to pump (systole). The heart rhythms are picked up through a computerized EKG machine. The benefits of EECP include increased blood flow to the heart and coronary arteries, thereby enabling the heart to perform at an optimal level.

Using data from the International EECP Patient Registry, the study included 363 patients age 67 and older with chest pain accompanied by severe left ventricular dysfunction. Patients underwent 32 one-hour EECP sessions five days a week for seven weeks. Prior to the study most of the patients reported that their quality of life was poor. Among the patients in the study, 85 percent previously had a heart attack, 72 percent had coronary bypass and 70 percent had some other type of invasive heart procedure. All patients were assessed at six months, one year and two years. By the end of the study, the patients reported significantly less chest pain and an improvement in quality of life. The overall two year survival rate was 83 percent and event-free survival rate was 70 p
'"/>


27-Feb-2006


Page: 1 2

Related medicine news :

1. Enhanced depression care may be cost-effective for employers
2. Enhanced brain response to smoking cues found in African American compared with caucasian smokers
3. Enhanced imaging techniques could improve medical diagnosis
4. FDA safety alerts for automated external defibrillators occur frequently
5. Automated external defibrillators are frequently recalled
6. New data finds recalls of automated external defibrillators to be common
7. CPR and external defibrillator training may decrease adolescent sports-related deaths
8. Nonhormonal drug reduces hot flashes in men treated for prostate cancer
9. Circumcision reduces HIV infection risk
10. Retinol lotion reduces the fine wrinkles from natural aging of skin
11. Improving communication with families of dying patients reduces stress, anxiety and depression

Post Your Comments:
(Date:7/24/2014)... (PRWEB) July 24, 2014 The ... Association (AOA) and the Entertainment Industries Council (EIC) ... TV series American Horror Story on a first-of-its-kind ... the dramatic realities of illegal and unsafe lens ... which has already reached tens-of-thousands, is now releasing ...
(Date:7/24/2014)... -- A new formulation of a powerful narcotic painkiller ... drug has been approved by the U.S. Food and ... Purdue Pharma, the pill is a combination of the ... euphoric effects of oxycodone. The naloxone is only activated ... according to the FDA. While Targiniq has only ...
(Date:7/24/2014)... 17, 2014, Cleveland: Could the body,s own immune system ... associated with conditions like chronic epilepsy, Alzheimer,s dementia and ... study published online by PLOS ONE . , ... known as S100B, which serves as a biomarker for ... brain and spinal column. However, following a brain injury, ...
(Date:7/24/2014)... July 24, 2014 National Analysts Worldwide, ... that it will operate globally under the name, ... a woman-owned Employee Stock Ownership Plan (ESOP) organization led ... McDonald, Ph.D . The firm guides market strategy ... analytics. , Said McDonald, “We wanted our name ...
(Date:7/24/2014)... The report, “Feed Palatability Enhancers & Modifiers ... Poultry, Cattle, Pets, Aquaculture, and Others) - Global Trends ... palatability enhancers & modifiers market with an analysis and ... of types of feed flavors, sweeteners, and text rants. ... spread through 275 pages and in-depth TOC on "Feed ...
Breaking Medicine News(10 mins):Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 2Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 4Health News:FDA Approves Hard-to-Abuse Narcotic Painkiller 2Health News:Immune response may cause harm in brain injuries, disorders 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 2Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 4
(Date:7/24/2014)...  Blueprint Medicines (Blueprint), a leader in discovering highly ... announced the appointment of Jeffrey Albers as ... Algeta ASA, where he served on the executive management ... Bayer. Mr. Albers succeeds Alexis Borisy , co-founder ... Rock Ventures, who will remain an active member of ...
(Date:7/24/2014)... SAN DIEGO , July 24, 2014 /PRNewswire/ ... the industry leader in bioactive lipid-targeted therapeutics, reported ... trial where ASONEP™ is being investigated as a ... patients that have failed at least one therapy ... and no more than one mTOR inhibitor (e.g., ...
(Date:7/24/2014)... 24, 2014  Market Diagnostics International LLC ("MDxI") ... LabFile , a data resource that sets a ... universe and identifying target In Vitro Diagnostics (IVD) ... that provides IVD manufacturers with accurate and comprehensive ... clear and consistent definitions of laboratory categories and ...
Breaking Medicine Technology:Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 3Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 4MDxI Launches Data Resource Setting New Standard for Defining and Targeting US Clinical Laboratory Universe 2
Cached News: